Ranjbar MA, Ranjbar
Z, Zahed M, Nikookar N.
CD73 a novel marker for the diagnosis of benign and malignant salivary gland
tumors. J Clin Exp Dent.
2019;11(3):e213-8.
doi:10.4317/jced.54918
http://dx.doi.org/10.4317/jced.54918
______________________________________________________________________________________________________________________________________
References
|
1. Zimmermann H.
50-Nucleotidase: molecular structure and functional aspects. Biochem J. 1992;285:345-65. |
|
|
|
|
|
2. Mills JH, Thompson LF,
Mueller C, Waickman AT, Jalkanen
S, Niemela J, et al. CD73 is required for efficient entry of lymphocytes into
the central nervous system during experimental autoimmune encephalomyelitis. Proc Natl Acad Sci
USA. 2008;105:9325-30. |
|
|
|
|
|
3.
Peng Z, Fernandez P,
Wilder T, Yee H, Chiriboga L, Chan ESL, et al. Ecto-5′-nucleotidase
(CD73)-mediated extracellular
adenosine production plays a critical role in hepatic fibrosis. FASEB J. 2008;22:2263-72. |
|
|
|
|
|
4. Castrop
H, Huang Y, Hashimoto S, Mizel D, Hansen P, Theilig F, et al. Impairment of tubuloglomerular
feedback regulation of GFR in ecto-5′-nucleotidase/CD73-deficient mice. J Clin Invest. 2004;114:634-42. |
|
|
|
|
|
5. Eckle
T, Krahn T, Grenz A,
Kohler D, Mittelbronn M, Ledent
C, et al. Cardioprotection by ecto-5′-nucleotidase
(CD73) and A2B adenosine receptors. Circulation. 2007;115:1581-90. |
|
|
|
|
|
6.
Thompson LF, Eltzschi HK, Ibla
JC, Van De Wiele CJ, Resta R, Morote-Garcia
JC, et al. Crucial role for ecto-5′-nucleotidase (CD73) in
vascular leakage during hypoxia. J Exp Med. 2004;200:1395-1405 |
|
|
|
|
|
7.
Koszalka P, Ozuyaman B, Huo Y, Zernecke A, Flogel U, Braun N, et al. Targeted disruption of cd73/ecto-5′-nucleotidase alters thromboregulation and augments vascular inflammatory
response. Circ Res. 2004;95:814-21. |
|
|
|
|
|
8. Canbolat
O, Durak I, Cetin R, Kavutcu
M, Demirci S, Ozturk S.
Activities of adenosine deaminase, 5′-nucleotidase, guanase,
and cytidine deaminase enzymes in cancerous and non-cancerous human breast
tissues. Breast Cancer Res Treat. 1996;37:189-93. |
|
|
|
|
|
9. Durak
I, Cetin R, Canbolat O, Cetin D, Yurtarslani Z, Unal A.
Adenosine deaminase, 5′-nucleotidase, guanase and
cytidine deaminase activities in gastric tissues from patients with gastric
cancer. Cancer Lett. 1994;84:199-202. PMid:8076377 |
|
|
|
|
|
10. Flocke
K, Mannherz HG. Isolation and characterization of
5′-nucleotidase of a human pancreatic tumor cell line. Biochim Biophys Acta. 1991;1076:273-81. PMid:1998727 |
|
|
|
|
|
11. Jin
D, Fan J, Wang L, Thompson LF, Liu A, Daniel BJ, et al. CD73 on tumor cells
impairs antitumor T-cell responses: a novel mechanism of tumor- induced
immune suppression. Cancer Research. 2010;70:2245-55. |
|
|
|
|
|
12. Sadej
R, Skladanowski AC. Dual, enzymatic and non-
enzymatic, function of ecto-5 -nucleotidase (eN, CD73) in migration and invasion of A375 melanoma
cells. Acta Biochimica Polonica. 2012;59:647-52. |
|
|
|
|
|
13.
Stella J, Bavaresco L, Braganhol
E, Rockenbach L, Fernandes
Farias P, et al. Differential ectonucleotidase expression in
human bladder cancer cell lines. Urologic Oncology: Seminars and Original
Investigations. 2010;28:260-7. |
|
|
|
|
|
14. Gao Z, Dong K, Zhang H.
The roles of CD73 in cancer. BioMed research international.
2014;2014. |
|
|
|
|
|
15. Liu N, Fang XD, Vadis Q.
CD73 as a novel prognostic biomarker for human colorectal cancer. Journal of Surgical Oncology. 2012;106:918-9. |
|
|
|
|
|
16.
Wu X, He X, Chenetal Y,
Yuan R, Zeng Y, Lian L,
et al. High expression of CD73 as a poor prognostic
biomarker in human colorectal cancer. Journal of Surgical Oncology. 2012;106:130-7. |
|
|
|
|
|
17. Oh HK, Sin JI, Choi J,
Park SH, Lee TS, Choi YS. Overexpression of CD73 in epithelial ovarian
carcinoma is associated with better prognosis, lower stage, better di er- entiation and lower
regulatory t cell in ltration. Journal of
Gynecologic Oncology. 2012;23:274-81. |
|
|
|
|
|
18. Lu XX, Chen YT, Feng B,
Mao XY, Yu B, Chu X. Expression and clinical signi cance of CD73 and hypoxia- inducible factor-1α in gastric carcinoma. World Journal of
Gastroenterology. 2013;19:1912-8. |
|
|
|
|
|
19. Xiong
L, Wen Y, Miao X, Yang Z. NT5E and FcGBP as key
regulators of TGF-1-induced epithelial-mesenchymal transition (EMT) are
associated with tumor progression and survival of patients with gallbladder
cancer. Cell and Tissue Research. 2014;355:365-74. |
|
|
|
|
|
20.
Zhao SX, Zhang HM, Dong SX, Liu
JH, Zhou Z, Wang HJ, et al. Characteristics and clinical signicance
of CD73 expression in subtypes of leukemia. Journal of experimental
hematology/Chinese Association of Pathophysiology. 2011;19:1141-4. |
|
|
|
|
|
21. Serra S, Horenstein AL, Vaisitti T, Brusa D, Rossi D, Laurenti L,
et al. CD73-generated extracellular adenosine in chronic lymphocytic leukemia
cre- ates local
conditions counteracting drug-induced cell death. Blood. 2011;118:6141-52. |
|
|
|
|
|
22. Wieten
E, Linden-Schrever BEM, Sonneveld
E, Veerman AJ, Pieters R.
CD73 (5-nucleotidase) expression has no prognostic value in children with
acute lymphoblastic leukemia. Leukemia.201;25:1374-6. PMid:21760591 |
|
|
|
|
|
23. Yang Q, Du J, Zu L. Overexpression of CD73 in prostate cancer is
associated with lymph node metastasis. Pathology Oncology Research. 2013;19:811-4. |
|
|
|
|
|
24.
Supernat A, Wełnicka-Jaskiewicz
M, Markiewicz A, Seroczyńska
B, Skokowski J, Sejda A,
et al. CD73 expression as a potential marker of good
prognosis in breast carcinoma. Applied Immunohistochemistry and Molecular
Morphology.2012;20:103-7. |
|
|
|
|
|
25. Loi
S, Pommey S, Haibe-Kains
B, Beavis PA, Darcy PK, Smyth MJ, et al. CD73 promotes anthracycline
resistance and poor prognosis in triple negative breast cancer. Proceedings
of the National Academy of Sciences of the United States of America. 2013;110:11091-6. |
|
|
|
|
|
26.
Ren ZH, Yuan YX, Ji T, Zhang CP. CD73 as a novel marker for poor prognosis of oral
squamous cell carcinoma. Oncology Letters. 2016;12:556-62. |
|
|
|
|
|
27. Ghazy
SE, Helmy IM, Baghdadi HM. Maspin
and MCM2 immunoprofiling in salivary gland
carcinomas. Diagnostic pathology. 2011;6:89. |
|
|
|
|
|
28. Speight PM, Barrett AW.
Salivary gland tumors. Oral
Dis. 2002;8:229-40. |
|
|
|
|
|
29. Barnes L, Eveson J, Reichart P, Sidransky D. Salivary glands Pathology and genetics of
head and neck tumors. Edited by: Barnes L. 2005, Lyon: IARC Press,
212-213. |
|
|
|
|
|
30. Ashkavandi
ZJ, Najvani AD, Tadbir
AA, Pardis S, Ranjbar MA,
Ashraf MJ. MCM3 as a novel diagnostic marker in benign and malignant salivary
gland tumors. Asian Pac Cancer Prev.
2013;14:3479-82. PMid:23886132 |
|
|
|
|
|
31. Wang L, Fan J, Thompson
LF, Zhang Y, Shin T, Curiel TJ, et al. CD73 has
distinct roles in non hematopoietic
and hematopoietic cells to promote tumor growth in mice. J Clin Invest. 2011;121:2371-82 |
|
|
|
|
|
32. Eroglu
A, Canbolat O, Demirci S,
Kocaoĝlu H, Eryavuz Y, Akgül H. Activities of adenosine deaminase and
5'-nucleotidase in cancerous and noncancerous human colorectal tissues. Med Oncol. 2000;17:319-24. |
|
|
|
|
|
33. Colgan
SP, Eltzschig HK, Eckle
T, Thompson LF. Physiological roles for ecto-5 -nucleotidase
(CD73). Puriner-gic Signalling.
2006;2:351-60. |
|